8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 16, 2015

Sevion Therapeutics, Inc.

 (Exact Name of Registrant as Specified in Charter)

Delaware	001-31326	84-1368850
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

4045 Sorrento Valley Boulevard, San Diego, California	92121
(Address of Principal Executive Offices)	(Zip Code)

(858) 909-0749

(Registrant's telephone number,

including area code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Item 8.01 Other Events.

On June 16, 2015, Sevion Therapeutics, Inc. (the “Company”) issued a press release announcing the presentation of an overview of the Company’s technology and programs by Dr. Miguel de los Rios, Ph.D., the Company’s Vice President of Research and Development. The presentation was made at the 2015 BIO International Convention in Philadelphia, Pennsylvania.

A copy of the press release is filed as Exhibit 99.1 hereto and incorporated herein by reference.

A copy of the presentation materials can be found on the Company’s website at www.SevionTherapeutics.com.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

     99.1 Press Release of Sevion Therapeutics, Inc. dated June 16, 2015.

- 2 -

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	SEVION THERAPEUTICS, INC.
Dated: June 16, 2015	By:	/s/ David Rector
	Name: Title:	David Rector Chief Executive Officer

EX-99.1

Exhibit 99.1

Sevion Therapeutics Announces Immuno Oncology Discovery Program at BIO

SAN DIEGO, CA – June 16, 2015 – Sevion Therapeutics, Inc. (“Sevion” or the “Company”) (OTCQB: SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today provided an overview of the Company’s technology and programs by Dr. Miguel de los Rios, PhD, VP of Research and Development, at the BIO International Convention in Philadelphia, PA.

Technology Platform and Discovery Efforts. The Company has successfully completed an antibody discovery screening effort on both internal and partnered targets. The internal discovery program includes novel oncology GPCR targets. “To our knowledge we have the first antibodies against certain important GPCRs associated with several cancers,” said Dr. de los Rios. The Company believes it has a position in the expanding field of immuno oncology, where several transmembrane proteins are currently not drugged due to discovery technology limitations. “Our proprietary platform for discovering antibodies against multipass membrane proteins provides a unique opportunity for us to target pathways in immuno oncology that regulate T-cell destruction of cancers. Additionally, our core capabilities are in immunology and oncology, so antibody discovery and development in this area will play to our strengths,” noted Dr. de los Rios. Additionally, the Company has expanded and optimized production of its arrayed antibody library, which will enhance the efficiency by which it discovers leads for difficult transmembrane targets.

SVN-001 Development. The Company’s humanized cow antibody targeting the ion channel Kv1.3 for autoimmune disease was engineered to have a unique dual mode of action, which has been confirmed in T-cell inhibitory assays. The potency of SVN-001 is in the subnanomolar range in vitro.

Business Development and Financing. The Company continues to pursue partnering opportunities for its technology and drug candidates, particularly in the areas of ion channel and GPCR antibody discovery. As previously disclosed, the Company has recently entered into subscription agreements with investors closing on net proceeds to the Company of approximately $4 million.

About Sevion Therapeutics

Sevion Therapeutics is a biopharmaceutical company building and developing a portfolio of innovative therapeutics, from both internal discovery and acquisition, for the treatment of cancer and immunological diseases. The Company’s product candidates are derived from multiple key proprietary technology platforms: cell-based arrayed antibody discovery, ultralong antibody scaffolds and Chimerasome nanocages. Sevion has leveraged these technologies to build a pipeline of innovative product candidates. For more information, please visit SevionTherapeutics.com.

1

Forward-Looking Statements

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the Company’s ability to continue as a going concern; the ability of the Company to consummate additional financings; the development of the Company’s antibody technology; the approval of the Company’s patent applications; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company’s products; the timing and success of the Company’s preliminary studies, preclinical research and clinical trials; competition and the timing of projects and trends in future operating performance; and the quotation of the Company’s common stock on an over-the-counter securities market, as well as other factors expressed from time to time in the Company’s periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company’s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

For investors contact:

Sevion Therapeutics

858-909-0749

2